Harvard Bioscience (HBIO) Return on Sales (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Sales rose 2.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (up 1.0% YoY) and the FY2025 annual result came in at 0.01%, down 1.0% from the prior year.
• Return on Sales declined to 0.0% in Q1 2026 per HBIO's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q2 2022 and bottomed at 0.02% in Q1 2025.
• The 5-year median for Return on Sales is 0.0% (2025), against an average of 0.0%.
• The widest annual swing landed in 2025, when Return on Sales slipped 2 bps; it then grew 2 bps in 2026.
• Tracing HBIO's Return on Sales over 5 years: stood at 0.0% in 2022, then climbed by 26 bps to 0.0% in 2023, then surged by 101 bps to 0.0% in 2024, then sank by 19642 bps to 0.0% in 2025, then fell by 15 bps to 0.0% in 2026.
• Per Business Quant, the three latest HBIO Return on Sales figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).

Peer Comparison